Featured Press Releases

FDA Approves Myhibbin™ by Azurity Pharmaceuticals, Inc., a Mycophenolate Mofetil Oral Suspension

FDA Approves Myhibbin™ by Azurity Pharmaceuticals, Inc., a Mycophenolate Mofetil Oral Suspension

Emulate introduces the AVA™ Emulation System, a groundbreaking high-throughput organ-chip platform designed to accelerate drug development

Emulate introduces the AVA™ Emulation System, a groundbreaking high-throughput organ-chip platform designed to accelerate drug development

  • 10 Jun 2025

Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial...

ONFAB, High Potent Containment Provider, Expands into USA Market

ONFAB, High Potent Containment Provider, Expands into USA Market

CollPlant Biotechnologies Announces First Quarter 2025 Financial Results and Issues Corporate Update

CollPlant Biotechnologies Announces First Quarter 2025 Financial Results and Issues Corporate Update

To advance gene therapy development and manufacturing, ProBio has launched GMP AAV manufacturing services at its Hopewell facility

To advance gene therapy development and manufacturing, ProBio has launched GMP AAV manufacturing services at its Hopewell facility

Avenacy Announces the U.S. Launch of Bortezomib for Injection

Avenacy Announces the U.S. Launch of Bortezomib for Injection

Virax Biolabs CEO James Foster Updates Shareholders Following the Fiscal 2026 Annual Report and Commercial Supply Agreement with Fosun Diagnostics

Virax Biolabs CEO James Foster Updates Shareholders Following the Fiscal 2026 Annual Report and Commercial Supply Agreement with Fosun Diagnostics

  • Virax BioLabs Group Limited
  • 16 Jul 2026
Children

Children's Hospital of Philadelphia Initiative Substantially Increases Naloxone Co-Prescribing When Prescribing Outpatient Opioids

  • Children's Hospital of Philadelphia
  • 16 Jul 2026
Hologic’s Aptima® HPV Test Receives Expanded CE-IVDR Mark to Include Self-Collected Samples for Cervical Cancer Screening

Hologic’s Aptima® HPV Test Receives Expanded CE-IVDR Mark to Include Self-Collected Samples for Cervical Cancer Screening

  • Hologic, Inc.
  • 14 Jul 2026
Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX Approved by the European Commission as a First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX Approved by the European Commission as a First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

  • Merck
  • 14 Jul 2026
BioMarin

BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia Accepted by the U.S. Food and Drug Administration

  • BioMarin Pharmaceutical Inc.
  • 13 Jul 2026
FDA Approves Expanded Indication for Octapharma USA

FDA Approves Expanded Indication for Octapharma USA's wilate® for Prophylaxis of von Willebrand Disease in Children Younger Than 6 Years

  • Octapharma
  • 10 Jul 2026
The Digital Pharma Advances Conference 2026

Most Popular
July   2026
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.